Pipeline
The Best Target & The Best Chemical
PHI-101-OC was derived from the analysis of indications expansion using Pharos iBio's big data & AI-based new drug development platform. It is being developed for patients with platinum-resistant/refractory ovarian cancer, and is currently used to evaluate safety, tolerability and pharmacokinetic properties. Phase 1 clinical trials are in progress in Korea.
-
Absence of targeted therapy for
recurrent ovarian cancer
48% of patients with recurrent
ovarian cancer were platinum
resistant or refractory -
Except for PARP1 therapy for BRCA
mutations (8-18%), no treatment
for recurrent ovarian cancer
Platinum-resistant/refractory ovarian cancer
- Drug repurposing by Chemiverse about PHI-101
- First-in-Class CHK2 inhibitor
- Better anti-tumor effect than Olaparib regardless of BRCA mutation
- Superior in BRCA wild type patients derived primary cell
- Up to 44% advanced DCR in Clinical Trial Phase I
- Up to 68% reduced adverse effect than competing drug in Clinical Trial Phase I
-
Number of patients About 30,000 people
-
Market size KRW 5.3T (2023) Target Market
- PARP1 Inhibitors Market in Ovarian Cancer
Sources : Decision Resources Group, 2020 Disease Landscape & Forecast of Ovarian Cancer